Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Work In Process (2018 - 2024)

IGC Pharma (IGC) has disclosed Work In Process for 7 consecutive years, with $2000.0 as the latest value for Q3 2024.

  • On a quarterly basis, Work In Process fell 81.82% to $2000.0 in Q3 2024 year-over-year; TTM through Sep 2024 was $2000.0, a 81.82% decrease, with the full-year FY2023 number at $18000.0, down 96.92% from a year prior.
  • Work In Process was $2000.0 for Q3 2024 at IGC Pharma, down from $36000.0 in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $3.9 million in Q3 2020 to a low of $2000.0 in Q3 2024.
  • A 5-year average of $1.7 million and a median of $2.2 million in 2020 define the central range for Work In Process.
  • Peak YoY movement for Work In Process: surged 1397.18% in 2020, then crashed 96.92% in 2023.
  • IGC Pharma's Work In Process stood at $2.2 million in 2020, then grew by 0.41% to $2.2 million in 2021, then plummeted by 71.56% to $628000.0 in 2022, then crashed by 98.25% to $11000.0 in 2023, then tumbled by 81.82% to $2000.0 in 2024.
  • Per Business Quant, the three most recent readings for IGC's Work In Process are $2000.0 (Q3 2024), $36000.0 (Q2 2024), and $11000.0 (Q3 2023).